Table 1

Demographic, clinical and neurocognitive characteristics of study participants*

CharacteristicHealthy controlsPatients without TRDPatients with TRDANOVA, F2p value (ANOVA)LSDp value (Kruskal–Wallis test)
Age, yr65.6 ± 7.765.3 ± 8.566.5 ± 6.00.1790.8
No. (%) female21 (77.8)21 (77.8)22 (81.5)0.1490.9
Duration, yr12.2 ± 9.715.8 ± 14.31.1520.3
HDRS-17 score1.3 ± 1.77.0 ± 5.721.1 ± 9.567.208< 0.001Healthy controls < patients without TRD < patients with TRD< 0.001
Finger tapping (times)26.0 ± 6.523.7 ± 6.920.7 ± 9.23.1440.05Healthy controls > patients with TRD
Verbal fluency (word counts)3.8 ± 2.13.1 ± 2.02.7 ± 2.02.0500.1
Dual task (word counts)4.2 ± 2.43.0 ± 1.92.9 ± 1.92.9400.06Healthy controls > patients with TRD
WCST, % error47.38 ± 20.5847.40 ± 17.9057.56 ± 21.632.2870.1
WCST, % conceptual level37.35 ± 26.4038.48 ± 23.5827.22 ± 25.971.6100.2
WCST, category completed2.27 ± 2.382.93 ± 2.091.48 ± 2.013.0230.05
  • ANOVA = analysis of variance; HDRS-17 = Hamilton Depression Rating Scale (17 items); LSD = least significant difference; TRD = treatment-resistant depression; WCST = Wisconsin Card Sorting Test.

  • * All data are given as means ± SDs unless specified otherwise.